Zynnon develops filtration and disinfection systems that utilize high-efficiency particulate air (HEPA) filters and ultraviolet (UV) light technology to reduce airborne pathogens in healthcare settings. This technology enhances patient safety by significantly lowering the transmission rates of respiratory infections in hospitals and clinical environments.
Funding
$836.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional pathogen detection methods in clinical diagnostics and industrial microbiology can be slow, complex, and costly, hindering timely intervention and potentially leading to increased antibiotic consumption and antimicrobial resistance. Current methods often lack the speed and simplicity needed for effective bedside monitoring and rapid identification of bloodstream infections.
Solution
Zynnon is developing a diagnostic solution that enhances pathogen identification through the detection of gas biomarkers, leveraging AI to improve the speed and accuracy of results. This technology aims to simplify the process of pathogen detection and identification, leading to lower costs of care and a reduction in antibiotic consumption, addressing the challenge of antimicrobial resistance (AMR). By focusing on non-invasive bedside monitoring and rapid species-level identification, Zynnon's approach seeks to provide faster, actionable information to clinicians, ultimately improving patient outcomes, especially in cases of sepsis and bacteremia. The company's technology enhances gold standard pathogen cultures, offering a streamlined and efficient method for identifying infectious diseases.
Target Audience
Zynnon's primary target audience includes clinical diagnostics and industrial microbiology markets, specifically hospitals, clinical environments, and laboratories seeking faster and more accurate pathogen identification methods.
Features
- AI-driven analysis of gas biomarkers to enhance pathogen identification
- Non-invasive bedside monitoring capabilities
- Rapid species-level identification of bloodstream infection pathogens
- Technology to enhance gold standard pathogen cultures
- Streamlined process for pathogen detection and identification